The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

A finding by a McGill-led team of neuroscientists could open doors to new treatments for a range of psychiatric and neurological disorders attributed to dysfunctions in specific dopamine pathways. For ...

However, the opioid pathway, a heavily studied physiologic pathway inextricably intertwined with behaviour and reward, rarely receives attention within psychiatric practice. Although the opioid system ...

A genetic postmortem analysis of the brains of patients with schizophrenia suggests dysfunction of dopamine receptors in the caudate nucleus may cause the disorder. Investigators identified a ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how scientists think about Parkinson's disease treatments. Published in Nature ...

For decades, Parkinson’s disease has been framed as a simple story of dwindling dopamine, a slow erosion of the brain’s movement signal. A wave of new research is now overturning that picture, ...

This is part 4 of a 5-part series on modern perspectives on ADHD. Part 3, "Is ADHD Really a Disorder?" is available here. If a distinct population of individuals have something we describe as ADHD, ...